GlassScriptPhysician profile
Jerlyn C Mccleod
NPI 1972659407
$9,370.92
in general payments reported to CMS, 2019-2025
28 companies · $1,844 in 2025
The $1,844 reported for 2025 was more than what 93% of Child & Adolescent Psychiatry providers received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $544 · 2020: $239 · 2021: $838 · 2022: $1,272 · 2023: $1,624 · 2024: $3,010 · 2025: $1,844.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,478.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,477.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $1,384.68 | 2021-2025 | Azstarys |
| Janssen Pharmaceuticals, INC | $1,358.64 | 2019-2025 | Spravato, Invega Sustenna |
| Supernus Pharmaceuticals, INC. | $770.77 | 2021-2024 | Qelbree, Qelbree |
| Abbvie INC. | $769.81 | 2021-2025 | |
| Vanda Pharmaceuticals INC. | $706.85 | 2019-2025 | Fanapt |
| Otsuka America Pharmaceutical, INC. | $680.76 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Almatica Pharma LLC | $578.49 | 2022-2025 | Loreev Xr, Sertraline Hcl |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $493.73 | 2021-2025 | Caplyta |
| Tris Pharma INC | $413.32 | 2019-2025 | Dyanavel Xr |
| Ironshore Pharmaceuticals INC. | $400.64 | 2019-2024 | Jornay Pm |
| Takeda Pharmaceuticals U.S.A., INC. | $292.63 | 2020-2024 | Trintellix |
| Alkermes, INC. | $230.22 | 2022-2025 | Aristada, Lybalvi |
| Axsome Therapeutics, INC. | $187.48 | 2022-2025 | Auvelity, Sunosi |
| Neurocrine Biosciences, INC. | $161.62 | 2021-2025 | Ingrezza |
| Neos Therapeutics, LP | $143.17 | 2019-2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $128.90 | 2020-2022 | |
| Teva Pharmaceuticals USA, INC. | $108.93 | 2022-2024 | Austedo Xr |
| Allergan, INC. | $106.66 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $103.58 | 2020-2022 | |
| Shire North American Group INC | $68.85 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $65.71 | 2024-2025 | Cobenfy |
| Collegium Pharmaceutical, INC. | $49.53 | 2025 | Jornay Pm |
| Merck Sharp & Dohme LLC | $39.70 | 2022-2023 | Belsomra |
| Acadia Pharmaceuticals INC | $36.31 | 2024-2025 | Daybue, Nuplazid |
| Idorsia Pharmaceuticals US INC | $34.96 | 2022 | |
| Lundbeck LLC | $20.43 | 2020 | |
| Sage Therapeutics, LLC | $18.66 | 2024 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $15.89 | 2025 | Rejoyn |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jerlyn Mccleod listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.